Orin
APDNYSE·Chemicals - Specialty

Air Products and Chemicals, Inc. APD

Market cap $64.1BP/E no earnings to divide byGross margin 32.1%Reports Thu 5 Nov, before the open
$287.71
+0.74 (+0.26%)live 09:30 ET
52-wk $229.11 – $314.87
Watch
Orin's take
0.62conviction · moderate
Refreshed 31 Jul · take v6. A new filing or a print queues the next refresh.

Air Products is a hold because the underlying business is inflecting positively—Q3 FY26 adjusted EPS of $3.47 beat guidance, full-year adjusted EPS guidance was raised to $13.39–$13.49, and FY2026 capex is now expected at ~$3.5B versus $7.0B in FY2025, which should finally push free cash flow positive after three consecutive years of negative FCF. However, the stock at $300 trades at a 50% P/S premium and a 215% EV/EBITDA premium to the peer median, total debt has more than doubled to $18.4B from $8.3B three years ago, and GAAP results remain distorted by $2.1B in Q3 charges from the June 30, 2026 business and asset actions.

The turnaround thesis is real but largely priced in.

What could go wrong

  • Capex slippage delays FCF inflection. FY2026 capex guidance of ~$3.5B is a sharp reduction from $7.0B in FY2025, but APD has a track record of capex overruns—capex rose from $2.5B in FY2021 to $7.0B in FY2025. Any slippage pushes FCF positivity further out.
  • Balance sheet deterioration. Total debt grew from $8.3B (FY2022) to $18.4B (FY2025) while stockholders' equity fell from $17.0B to $15.0B. Sustained GAAP losses and large charges could further erode equity and raise leverage concerns.
  • Valuation premium unwinds. At $300, APD trades at 5.3x P/S and 64.8x EV/EBITDA versus peer medians of 3.5x and 20.6x respectively. If adjusted EPS growth disappoints or capex discipline falters, the premium could compress sharply.
  • Charge recurrence. Q3 FY26 included $2.1B in operating-loss charges from business and asset actions, following FY2025's $877M operating loss. Further portfolio actions could continue to distort GAAP results and erode investor confidence.

What would change my mind

FCF turns positive. FY2026 full-year free cash flow turns positive with capex at ~$3.5B and operating cash flow sustaining above $3.2Bbullish
Debt stabilization. Total debt stops increasing and begins declining from the $18.4B FY2025 peak as capex normalizesbullish
Adjusted EPS miss. Q4 FY26 adjusted EPS falls below the $3.55–$3.65 guidance range, signaling underlying business weakness beyond one-time chargesbearish
Capex guidance raised. FY2027 capex guidance exceeds $4B, suggesting the discipline narrative is breaking downbearish

Where this comes from: PRNewsWire Q3 FY26 results, 2026-07-30 · PRNewsWire Q3 FY26 results, 2026-07-30 · FMP FY2025 annual fundamentals · FMP multi-year fundamentals. Orin's read on APD; not advice.

Twelve months actual closes to 2026-09-23 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Vanguard Capital Management$4.3B0.1% of fund
Capital Research Global Investors$3.1B0.4% of fund
State Street$3.0B0.1% of fund
Vanguard Portfolio Management$2.6B0.1% of fund
Geode Capital Management$1.5B0.1% of fund
Jpmorgan Chase &$1.4B0.1% of fund

112 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 84 Form 4 filings, net −$22.2M. Of the 50 on hand, 0 were open-market purchases and 2 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about APD

its filings · its transcripts · its numbers

Orin answers questions about APD from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days

Where it trades

vs its own 5y · Basic Materials
MetricNowOwn medianSector
EV/EBITDA62.5×15.2×
P/S5.07×5.05×
P/B4.6×4.0×

Its P/E sits below all 5 of the last 5 years (−19.22σ from its own mean).

What Wall Street published

42 firms · 2026-09-23
Consensus target

$345

$320$373 · +20% against today's price

How they rate it
  • 22 buy or overweight
  • 20 hold
  • 0 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 29.8× of 7 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
APDAir Products and Chemicals, Inc.$64B62.5×32.1%-0.4%-0%
CTVACorteva, Inc.$54B53.3×17.4×48.5%5.7%4%
ECLEcolab Inc.$78B36.9×25.9×44.1%12.6%21%
FCXFreeport-McMoRan Inc.$104B35.8×12.3×26.8%11.4%15%
MLMMartin Marietta Materials, Inc.$29B12.0×16.9×28.2%36.8%23%
PPGPPG Industries, Inc.$24B15.3×10.7×40.1%9.6%19%
SHWThe Sherwin-Williams Company$79B29.8×20.9×49.1%11.0%62%
VMCVulcan Materials Company$32B28.8×14.2×27.4%13.8%13%

The median is of the 7 peers listed above and nothing else — check it against the column. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 25.8×FY24 17.3×

What its sector has traded at

Basic Materials
FY14 23.8×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$-200$281.32 · −171%2026-06-10
Levered DCF$-265$281.32 · −194%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $287.71
52-week range$229 – $315
Analyst targets$320 – $373
Standard DCF$-200 as of 2026-06-10, when it was $281.32
Levered DCF$-265 as of 2026-06-10, when it was $281.32

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.